Tag: GlobeNewswire

DES PLAINES, Ill., Oct. 06, 2026 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (NFI), a leading manufacturer of buses and motorcoaches and a provider of comprehensive aftermarket parts and service solutions, subsidiary Motor Coach Industries (MCI), today announced that New York City Transit (NYCT) has awarded a contract for 92 MCI D45 CRT commuter coaches.

Supported by state, local, and Metropolitan Transportation Authority (MTA) funding, the new coaches will replace aging vehicles operating on express bus routes, helping deliver comfortable, efficient transportation for customers. The order has been added to NFI’s third quarter 2026 backlog.

The MCI D45 CRT is purpose-built for high-capacity commuter and express operations, combining passenger comfort with the durability and performance transit agencies expect from MCI coaches.

“New York City Transit plays a vital role in connecting communities of the world’s largest and most dynamic metropolitan regions,” said Rob Marion, President, MCI. “We are proud to continue our longstanding partnership with NYCT and the broader MTA family by delivering high-quality commuter coaches that will enhance the customer experience and support consistent express bus service for riders. This investment reflects NYCT’s continued commitment to modernizing its fleet and providing safe, comfortable transportation for the millions of riders who depend on public transit every day.”

NYCT is a part of the MTA, which operates North America’s largest transportation network. The MTA oversees the nation’s largest bus fleet and more subway and commuter rail cars than all other U.S. transit systems combined, serving a population of 15.3 million across 5,000 square miles in New York City, Long Island, southeastern New York State, and Connecticut.

About NFI

NFI is a leading global bus and motorcoach manufacturer and a provider of aftermarket parts and service solutions. With more than 9,000 team members across ten countries and operations spanning over 40 facilities, NFI delivers a comprehensive portfolio of bus and coach platforms.

Through its brands New Flyer^® (heavy-duty transit buses), MCI^® (motorcoaches), Alexander Dennis Limited (single- and double-deck buses), ARBOC^® (low-floor cutaway and medium-duty buses), and NFI Parts™, NFI supports a diverse and extensive portfolio, serving public transit, commuter, and coach markets. In total, NFI supports an installed base of more than 100,000 buses and coaches worldwide. NFI offers a broad range of propulsion systems, including zero-emission electric (referring to propulsion systems that do not utilize internal combustion engines, such as trolley, battery, and fuel cell), natural gas, electric hybrid, and advanced diesel technologies, providing agencies with multiple fleet technology options. NFI’s common shares trade on the Toronto Stock Exchange (TSX: NFI) and its convertible unsecured debentures trade under the symbol NFI.DB. News and information is available at www.nfigroup.com, www.newflyer.com, www.mcicoach.com, nfi.parts, www.alexander-dennis.com, arbocsv.com, and carfaircomposites.com.

About MCI

MCI is North America’s leading manufacturer of public and private market motorcoaches. Products include the luxury J Series (an industry best-seller for more than two decades) and the workhorse D Series. MCI also provides maintenance, repair, 24-hour roadside assistance, parts, and technician training through the industry’s only Automotive Service Excellence (ASE) accredited and award-winning MCI Academy.

Forward-Looking Statements

This press release may contain forward-looking statements relating to expected future events and financial and operating results of NFI that involve risks and uncertainties. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, investors cannot be assured that actual results will be consistent with these forward-looking statements, and the differences may be material. Actual results may differ materially from management expectations as projected in such forward-looking statements for a variety of reasons, including market and general economic conditions (including as a result of tariffs and other trade measures) and economic conditions of and funding availability for customers to purchase buses and to purchase parts or services (including as a result of recent U.S. policy developments); customers may not exercise options to purchase additional buses; the ability of customers to suspend or terminate contracts for convenience; production may be delayed or production rates may be decreased as a result of ongoing and future supply chain disruptions and shortages of parts and components, shipping and freight delays, and disruption to and shortage of labor supply; and the other risks and uncertainties discussed in the materials filed with the Canadian securities regulatory authorities and available on SEDAR at www.sedarplus.ca.  

Due to the potential impact of these factors, NFI disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by applicable law. 

For media inquiries, please contact: 
Melissa Schnee 
P: 385.910.6861 
Melissa_Schnee@newflyer.com 

For investor inquiries, please contact: 
Stephen King 
P: 204.792.1300 
Stephen.King@nfigroup.com 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8a2cd546-f090-44f5-b72f-6c5fbcb8a0e4

Highlights

• High-Grade^** Uranium at Surface: A prospecting, mapping, and geochemical sampling program is planned for October 2026 to expand on newly identified and historical uranium-bearing outcrops including the Manhattan showing (1.19 to 8.10% U₃O₈)² and SMDI showing 2052 (0.137% U₃O₈ and 2,300 ppm Th).³
• Integration with Drilling Results: The results of the inaugural drill program on the Project clearly outlined a robust multi-kilometre uranium-bearing mineralized system across the Manhattan, Brooklyn, and Tribeca target areas. Drilling confirmed the presence of significant fault systems linked to uranium enrichment and prospective hydrothermal alteration in the basement rock, which will be further investigated in detail at surface during the Program.
• Follow Up Targets & Next Steps: Following the integration of additional surface exploration results with drilling and geophysical datasets, a second phase drilling program is being planned to continue testing along strike of mineralized drill holes in addition to priority regional drill targets. Several priority uranium targets remain along >25 km of structural strike length.

VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) — Aventis Energy Inc. (“Aventis” or the “Company”) (CSE: AVE | FRA: C0O0 | OTC: VBAMF) is pleased to announce plans for additional ground exploration at the Corvo Uranium Project (“Corvo”, or the “Project”), currently under a three-year earn-in option agreement (the “Option Agreement”) with Standard Uranium Ltd. (TSX-V: STND) (“Standard”). Exploration crews are scheduled to mobilize to site on October 1, 2026, to begin a detailed mapping and sampling program (the “Program”) across historical uranium showings and newly identified zones of interest.

The fall 2026 Program will focus on prospective areas around and along strike of successful drilling results from the winter 2026 drill campaign. Analytical results from the Company’s first-ever drill campaign at Corvo confirmed anomalous^* uranium in all nine (9) completed drill holes. Results returned a total of fifty-five (55) metres of weakly anomalous uranium (>10 ppm U, partial), including twenty-three (23) metres of moderately anomalous uranium (>50 ppm U, partial), and including thirteen (13) metres of highly anomalous uranium (>100 ppm U, partial).¹

Michael Mulberry, Chief Executive Officer & Director of Aventis, commented, “The fall program is the natural next step following the success of our inaugural drill campaign at Corvo. With crews returning to the ground in October, we have the opportunity to tie detailed mapping and sampling directly to the structures, alteration and uranium enrichment identified in drilling, and to expand on high-grade surface showings such as Manhattan. Combined with the ongoing geophysical work, this will sharpen our drill targets ahead of the second phase of drilling planned for 2027, and we look forward to continuing to advance the Project alongside Standard Uranium.”

Figure 1. Regional map of the Corvo Project. The Project is located 45 km northeast of Atha Energy’s Gemini Mineralized Zone and 60 km due east of Cameco’s McArthur River mine.

2026 Fall Exploration Program

Standard’s technical team is scheduled to mobilize to the Project on October 1, 2026, to undertake a detailed mapping, prospecting, and sampling Program to expand on known uranium showings and collect additional geological information at surface which can be linked to drill results. Collected grab samples will be transported to Saskatchewan Research Council Geoanalytical Laboratories in Saskatoon, SK for geochemical analysis. The Company will fund the exploration Program as part of the Option Agreement dated May 8, 2025⁴ and Standard will act as operator.

Supplementary geophysical work programs across the Project are also being designed to further refine drill targets for a 2027 drill program. Ongoing geophysical interpretation and modeling is planned throughout the remainder of 2026 to integrate drilling, geophysics, and prospecting datasets, which will further derisk drill targets across the Project prior to follow-up drilling next year.

The Company believes the Project is highly prospective for the discovery of shallow, high-grade^** basement-hosted uranium mineralization akin to the Rabbit Lake deposit and the recently discovered Gemini Mineralized Zone. Located just outside the current margin of the Athabasca Basin, Corvo boasts shallow drill targets with bedrock under minimal cover of glacial till. Several outcrop showings of mineralized veins and fractures are present on the Project, notably the Manhattan Showing that returned modern sample results up to 8.10% U₃O₈ at surface².

Qualified Person Statement

The scientific and technical information contained in this news release has been reviewed and approved by Sean Hillacre, P.Geo., President and VP Exploration of Standard Uranium Ltd. and a “qualified person” as defined in NI 43-101 – Standards of Disclosure for Mineral Projects.

Samples collected for analysis were sent to SRC Geoanalytical Laboratories (“SRC”) in Saskatoon, Saskatchewan for preparation, processing, and ICP-MS multi-element analysis using total and partial digestion and boron by fusion. Basement samples were tested with ICP-MS2 uranium multi-element exploration package plus boron. All sandstone samples, and basement samples marked as radioactive upon arrival to the lab were also analyzed using the U₃O₈ assay (reported in wt.%). Basement rock split interval samples range from 0.1 to 1.0 m. SRC is an ISO/IEC 17025/2005 and Standards Council of Canada certified analytical laboratory. Blanks, standard reference materials, and repeats were inserted into the sample stream at regular intervals in accordance with Standard’s quality assurance/quality control (“QA/QC”) protocols. All samples passed internal QA/QC protocols and the results presented in this release are deemed complete, reliable, and repeatable.

Historical data disclosed in this news release relating to sampling results from previous operators are historical in nature. Neither the Company nor a qualified person has yet verified this data and therefore investors should not place undue reliance on such data. The Company’s future exploration work may include verification of the data. The Company considers historical results to be relevant as an exploration guide and to assess the mineralization as well as economic potential of exploration projects. Any historical grab samples disclosed are selected samples and may not represent true underlying mineralization.

References

¹ News Release: Standard Uranium Confirms Uranium Enrichment in all Winter 2026 Drill Holes at the Corvo Uranium Project, https://www.standarduranium.ca/news-releases/standard-uranium-confirms-uranium-enrichment-in-all-winter-2026-drill-holes-at-the-corvo-uranium-project

² News Release: Standard Uranium Confirms High-Grade Uranium Mineralization up to 8.10% U₃O₈ at Surface on the Corvo Project, https://standarduranium.ca/news-releases/standard-uranium-confirms-high-grade-uranium-mineralization-at-surface-on-the-corvo-project/

³ SMDI# 2052: https://mineraldeposits.saskatchewan.ca/Home/Viewdetails/2052 & Mineral Assessment Report MAW00047: Eagle Plains Resources Inc., 2011-2012

⁴ News Release: Standard Uranium Announces Signing of Definitive Agreement to Option Corvo Project in Eastern Athabasca Basin, https://www.standarduranium.ca/news-releases/standard-uranium-announces-signing-of-definitive-agreement-to-option-corvo-project-in-eastern-athabasca-basin

^*In crystalline basement rocks, the Company considers concentrations of uranium >10 ppm U to be “weakly anomalous”, concentrations >50 ppm U to be “moderately anomalous” and concentrations >100 ppm U to be “highly anomalous”. Intervals represent drilled core lengths; True thicknesses of mineralized zones cannot be determined with certainty at this stage of exploration.

^**The Company considers uranium mineralization with concentrations greater than 1.0 wt.% U₃O₈ to be “high-grade”.

About Aventis Energy Inc. 

Aventis Energy Inc. (CSE: AVE | FRA: C0O0 | OTC: VBAMF) is a mineral exploration company dedicated to the development of strategic projects comprised of battery, base and precious metals in stable jurisdictions. The Company is working to advance its Corvo Uranium & Sting Copper Project.

The Corvo Uranium property has historical drill holes intersected multiple intervals of uranium mineralization, notably along a strike length of 800 metres between historical drill holes TL-79-3 (0.116% U₃O₈ over 1.05 m) and TL-79-5 (0.065% U₃O₈ over 0.15 m)². High-grade* Uranium at Surface with the Manhattan showing (with outcrop samples grab samples returning up to 8.10% U₃O₈) and SMDI showing 2052 (0.137% U₃O₈ and 2,300 ppm Th).

The Sting Copper Project covers approximately 3,700 hectares and recently had results of 54.8m at 0.32% Cu starting at a depth of 27.0m, with higher-grade intervals including six samples (≥0.5m length) ranging from 0.96% to 5.43% Cu. High grade samples of 0.5m at 2.85% Cu and 0.5m at 1.92% Cu with an additional broader interval of 31.1m at 0.27% Cu.

On Behalf of the Board of Directors

Michael Mulberry
Chief Executive Officer, Director
+1 (604) 229-9772
info@vitalbatterymetals.com

Disclaimer for Forward-Looking Information

This news release includes certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” under applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, expect”, “target”, “plan”, “forecast”, “may”, “would”, “could”, “schedule” and similar words or expressions, identify forward-looking statements or information.

Forward-looking statements and forward-looking information relating to any future mineral production, liquidity, enhanced value and capital markets profile of Aventis, future growth potential for Aventis and its business, and future exploration plans are based on management’s reasonable assumptions, estimates, expectations, analyses and opinions, which are based on management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect. Assumptions have been made regarding, among other things, the price of uranium, copper, gold and other metals; costs of exploration and development; the estimated costs of development of exploration projects; Aventis’ ability to operate in a safe and effective manner and its ability to obtain financing on reasonable terms.

This news release contains “forward-looking information” within the meaning of the Canadian securities laws. Statements, other than statements of historical fact, may constitute forward looking information and include, without limitation, statements with respect to the Project and its mineralization potential; the Company’s objectives, goals, or future plans with respect to the Project; further exploration work on the Project in the future; the expected benefits of completing the Program; the commencement of additional drilling program(s) on the Project in the future. With respect to the forward-looking information contained in this news release, the Company has made numerous assumptions regarding, among other things, the geological, metallurgical, engineering, financial and economic advice that the Company has received is reliable and are based upon practices and methodologies which are consistent with industry standards. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: fluctuations in commodity prices and currency exchange rates; uncertainties relating to interpretation of well results and the geology, continuity and grade of uranium, copper, gold and other metal deposits; uncertainty of estimates of capital and operating costs, recovery rates, production estimates and estimated economic return; the need for cooperation of government agencies in the exploration and development of properties and the issuance of required permits; the need to obtain additional financing to develop properties and uncertainty as to the availability and terms of future financing; the possibility of delay in exploration or development programs or in construction projects and uncertainty of meeting anticipated program milestones; uncertainty as to timely availability of permits and other governmental approvals; increased costs and restrictions on operations due to compliance with environmental and other requirements; increased costs affecting the metals industry and increased competition in the metals industry for properties, qualified personnel, and management. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

The Canadian Securities Exchange (CSE) does not accept responsibility for the adequacy or accuracy of this release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/13d8d50a-3944-475c-99f7-a8c5e9da5219

Highlights

• High-Grade^** Uranium at Surface: A prospecting, mapping, and geochemical sampling program is planned for October 2026 to expand on newly identified and historical uranium-bearing outcrops including the Manhattan showing (1.19 to 8.10% U₃O₈)² and SMDI showing 2052 (0.137% U₃O₈ and 2,300 ppm Th).³
• Integration with Drilling Results: The results of the inaugural drill program on the Project clearly outlined a robust multi-kilometre uranium-bearing mineralized system across the Manhattan, Brooklyn, and Tribeca target areas. Drilling confirmed the presence of significant fault systems linked to uranium enrichment and prospective hydrothermal alteration in the basement rock, which will be further investigated in detail at surface during the Program.
• Follow Up Targets & Next Steps: Following the integration of additional surface exploration results with drilling and geophysical datasets, a second phase drilling program is being planned to continue testing along strike of mineralized drill holes in addition to priority regional drill targets. Several priority uranium targets remain along >25 km of structural strike length.

VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) — Aventis Energy Inc. (“Aventis” or the “Company”) (CSE: AVE | FRA: C0O0 | OTC: VBAMF) is pleased to announce plans for additional ground exploration at the Corvo Uranium Project (“Corvo”, or the “Project”), currently under a three-year earn-in option agreement (the “Option Agreement”) with Standard Uranium Ltd. (TSX-V: STND) (“Standard”). Exploration crews are scheduled to mobilize to site on October 1, 2026, to begin a detailed mapping and sampling program (the “Program”) across historical uranium showings and newly identified zones of interest.

The fall 2026 Program will focus on prospective areas around and along strike of successful drilling results from the winter 2026 drill campaign. Analytical results from the Company’s first-ever drill campaign at Corvo confirmed anomalous^* uranium in all nine (9) completed drill holes. Results returned a total of fifty-five (55) metres of weakly anomalous uranium (>10 ppm U, partial), including twenty-three (23) metres of moderately anomalous uranium (>50 ppm U, partial), and including thirteen (13) metres of highly anomalous uranium (>100 ppm U, partial).¹

Michael Mulberry, Chief Executive Officer & Director of Aventis, commented, “The fall program is the natural next step following the success of our inaugural drill campaign at Corvo. With crews returning to the ground in October, we have the opportunity to tie detailed mapping and sampling directly to the structures, alteration and uranium enrichment identified in drilling, and to expand on high-grade surface showings such as Manhattan. Combined with the ongoing geophysical work, this will sharpen our drill targets ahead of the second phase of drilling planned for 2027, and we look forward to continuing to advance the Project alongside Standard Uranium.”

Figure 1. Regional map of the Corvo Project. The Project is located 45 km northeast of Atha Energy’s Gemini Mineralized Zone and 60 km due east of Cameco’s McArthur River mine.

2026 Fall Exploration Program

Standard’s technical team is scheduled to mobilize to the Project on October 1, 2026, to undertake a detailed mapping, prospecting, and sampling Program to expand on known uranium showings and collect additional geological information at surface which can be linked to drill results. Collected grab samples will be transported to Saskatchewan Research Council Geoanalytical Laboratories in Saskatoon, SK for geochemical analysis. The Company will fund the exploration Program as part of the Option Agreement dated May 8, 2025⁴ and Standard will act as operator.

Supplementary geophysical work programs across the Project are also being designed to further refine drill targets for a 2027 drill program. Ongoing geophysical interpretation and modeling is planned throughout the remainder of 2026 to integrate drilling, geophysics, and prospecting datasets, which will further derisk drill targets across the Project prior to follow-up drilling next year.

The Company believes the Project is highly prospective for the discovery of shallow, high-grade^** basement-hosted uranium mineralization akin to the Rabbit Lake deposit and the recently discovered Gemini Mineralized Zone. Located just outside the current margin of the Athabasca Basin, Corvo boasts shallow drill targets with bedrock under minimal cover of glacial till. Several outcrop showings of mineralized veins and fractures are present on the Project, notably the Manhattan Showing that returned modern sample results up to 8.10% U₃O₈ at surface².

Qualified Person Statement

The scientific and technical information contained in this news release has been reviewed and approved by Sean Hillacre, P.Geo., President and VP Exploration of Standard Uranium Ltd. and a “qualified person” as defined in NI 43-101 – Standards of Disclosure for Mineral Projects.

Samples collected for analysis were sent to SRC Geoanalytical Laboratories (“SRC”) in Saskatoon, Saskatchewan for preparation, processing, and ICP-MS multi-element analysis using total and partial digestion and boron by fusion. Basement samples were tested with ICP-MS2 uranium multi-element exploration package plus boron. All sandstone samples, and basement samples marked as radioactive upon arrival to the lab were also analyzed using the U₃O₈ assay (reported in wt.%). Basement rock split interval samples range from 0.1 to 1.0 m. SRC is an ISO/IEC 17025/2005 and Standards Council of Canada certified analytical laboratory. Blanks, standard reference materials, and repeats were inserted into the sample stream at regular intervals in accordance with Standard’s quality assurance/quality control (“QA/QC”) protocols. All samples passed internal QA/QC protocols and the results presented in this release are deemed complete, reliable, and repeatable.

Historical data disclosed in this news release relating to sampling results from previous operators are historical in nature. Neither the Company nor a qualified person has yet verified this data and therefore investors should not place undue reliance on such data. The Company’s future exploration work may include verification of the data. The Company considers historical results to be relevant as an exploration guide and to assess the mineralization as well as economic potential of exploration projects. Any historical grab samples disclosed are selected samples and may not represent true underlying mineralization.

References

¹ News Release: Standard Uranium Confirms Uranium Enrichment in all Winter 2026 Drill Holes at the Corvo Uranium Project, https://www.standarduranium.ca/news-releases/standard-uranium-confirms-uranium-enrichment-in-all-winter-2026-drill-holes-at-the-corvo-uranium-project

² News Release: Standard Uranium Confirms High-Grade Uranium Mineralization up to 8.10% U₃O₈ at Surface on the Corvo Project, https://standarduranium.ca/news-releases/standard-uranium-confirms-high-grade-uranium-mineralization-at-surface-on-the-corvo-project/

³ SMDI# 2052: https://mineraldeposits.saskatchewan.ca/Home/Viewdetails/2052 & Mineral Assessment Report MAW00047: Eagle Plains Resources Inc., 2011-2012

⁴ News Release: Standard Uranium Announces Signing of Definitive Agreement to Option Corvo Project in Eastern Athabasca Basin, https://www.standarduranium.ca/news-releases/standard-uranium-announces-signing-of-definitive-agreement-to-option-corvo-project-in-eastern-athabasca-basin

^*In crystalline basement rocks, the Company considers concentrations of uranium >10 ppm U to be “weakly anomalous”, concentrations >50 ppm U to be “moderately anomalous” and concentrations >100 ppm U to be “highly anomalous”. Intervals represent drilled core lengths; True thicknesses of mineralized zones cannot be determined with certainty at this stage of exploration.

^**The Company considers uranium mineralization with concentrations greater than 1.0 wt.% U₃O₈ to be “high-grade”.

About Aventis Energy Inc. 

Aventis Energy Inc. (CSE: AVE | FRA: C0O0 | OTC: VBAMF) is a mineral exploration company dedicated to the development of strategic projects comprised of battery, base and precious metals in stable jurisdictions. The Company is working to advance its Corvo Uranium & Sting Copper Project.

The Corvo Uranium property has historical drill holes intersected multiple intervals of uranium mineralization, notably along a strike length of 800 metres between historical drill holes TL-79-3 (0.116% U₃O₈ over 1.05 m) and TL-79-5 (0.065% U₃O₈ over 0.15 m)². High-grade* Uranium at Surface with the Manhattan showing (with outcrop samples grab samples returning up to 8.10% U₃O₈) and SMDI showing 2052 (0.137% U₃O₈ and 2,300 ppm Th).

The Sting Copper Project covers approximately 3,700 hectares and recently had results of 54.8m at 0.32% Cu starting at a depth of 27.0m, with higher-grade intervals including six samples (≥0.5m length) ranging from 0.96% to 5.43% Cu. High grade samples of 0.5m at 2.85% Cu and 0.5m at 1.92% Cu with an additional broader interval of 31.1m at 0.27% Cu.

On Behalf of the Board of Directors

Michael Mulberry
Chief Executive Officer, Director
+1 (604) 229-9772
info@vitalbatterymetals.com

Disclaimer for Forward-Looking Information

This news release includes certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” under applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, expect”, “target”, “plan”, “forecast”, “may”, “would”, “could”, “schedule” and similar words or expressions, identify forward-looking statements or information.

Forward-looking statements and forward-looking information relating to any future mineral production, liquidity, enhanced value and capital markets profile of Aventis, future growth potential for Aventis and its business, and future exploration plans are based on management’s reasonable assumptions, estimates, expectations, analyses and opinions, which are based on management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect. Assumptions have been made regarding, among other things, the price of uranium, copper, gold and other metals; costs of exploration and development; the estimated costs of development of exploration projects; Aventis’ ability to operate in a safe and effective manner and its ability to obtain financing on reasonable terms.

This news release contains “forward-looking information” within the meaning of the Canadian securities laws. Statements, other than statements of historical fact, may constitute forward looking information and include, without limitation, statements with respect to the Project and its mineralization potential; the Company’s objectives, goals, or future plans with respect to the Project; further exploration work on the Project in the future; the expected benefits of completing the Program; the commencement of additional drilling program(s) on the Project in the future. With respect to the forward-looking information contained in this news release, the Company has made numerous assumptions regarding, among other things, the geological, metallurgical, engineering, financial and economic advice that the Company has received is reliable and are based upon practices and methodologies which are consistent with industry standards. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: fluctuations in commodity prices and currency exchange rates; uncertainties relating to interpretation of well results and the geology, continuity and grade of uranium, copper, gold and other metal deposits; uncertainty of estimates of capital and operating costs, recovery rates, production estimates and estimated economic return; the need for cooperation of government agencies in the exploration and development of properties and the issuance of required permits; the need to obtain additional financing to develop properties and uncertainty as to the availability and terms of future financing; the possibility of delay in exploration or development programs or in construction projects and uncertainty of meeting anticipated program milestones; uncertainty as to timely availability of permits and other governmental approvals; increased costs and restrictions on operations due to compliance with environmental and other requirements; increased costs affecting the metals industry and increased competition in the metals industry for properties, qualified personnel, and management. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

The Canadian Securities Exchange (CSE) does not accept responsibility for the adequacy or accuracy of this release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/13d8d50a-3944-475c-99f7-a8c5e9da5219

Highlights

• High-Grade^** Uranium at Surface: A prospecting, mapping, and geochemical sampling program is planned for October 2026 to expand on newly identified and historical uranium-bearing outcrops including the Manhattan showing (1.19 to 8.10% U₃O₈)² and SMDI showing 2052 (0.137% U₃O₈ and 2,300 ppm Th).³
• Integration with Drilling Results: The results of the inaugural drill program on the Project clearly outlined a robust multi-kilometre uranium-bearing mineralized system across the Manhattan, Brooklyn, and Tribeca target areas. Drilling confirmed the presence of significant fault systems linked to uranium enrichment and prospective hydrothermal alteration in the basement rock, which will be further investigated in detail at surface during the Program.
• Follow Up Targets & Next Steps: Following the integration of additional surface exploration results with drilling and geophysical datasets, a second phase drilling program is being planned to continue testing along strike of mineralized drill holes in addition to priority regional drill targets. Several priority uranium targets remain along >25 km of structural strike length.

VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) — Aventis Energy Inc. (“Aventis” or the “Company”) (CSE: AVE | FRA: C0O0 | OTC: VBAMF) is pleased to announce plans for additional ground exploration at the Corvo Uranium Project (“Corvo”, or the “Project”), currently under a three-year earn-in option agreement (the “Option Agreement”) with Standard Uranium Ltd. (TSX-V: STND) (“Standard”). Exploration crews are scheduled to mobilize to site on October 1, 2026, to begin a detailed mapping and sampling program (the “Program”) across historical uranium showings and newly identified zones of interest.

The fall 2026 Program will focus on prospective areas around and along strike of successful drilling results from the winter 2026 drill campaign. Analytical results from the Company’s first-ever drill campaign at Corvo confirmed anomalous^* uranium in all nine (9) completed drill holes. Results returned a total of fifty-five (55) metres of weakly anomalous uranium (>10 ppm U, partial), including twenty-three (23) metres of moderately anomalous uranium (>50 ppm U, partial), and including thirteen (13) metres of highly anomalous uranium (>100 ppm U, partial).¹

Michael Mulberry, Chief Executive Officer & Director of Aventis, commented, “The fall program is the natural next step following the success of our inaugural drill campaign at Corvo. With crews returning to the ground in October, we have the opportunity to tie detailed mapping and sampling directly to the structures, alteration and uranium enrichment identified in drilling, and to expand on high-grade surface showings such as Manhattan. Combined with the ongoing geophysical work, this will sharpen our drill targets ahead of the second phase of drilling planned for 2027, and we look forward to continuing to advance the Project alongside Standard Uranium.”

Figure 1. Regional map of the Corvo Project. The Project is located 45 km northeast of Atha Energy’s Gemini Mineralized Zone and 60 km due east of Cameco’s McArthur River mine.

2026 Fall Exploration Program

Standard’s technical team is scheduled to mobilize to the Project on October 1, 2026, to undertake a detailed mapping, prospecting, and sampling Program to expand on known uranium showings and collect additional geological information at surface which can be linked to drill results. Collected grab samples will be transported to Saskatchewan Research Council Geoanalytical Laboratories in Saskatoon, SK for geochemical analysis. The Company will fund the exploration Program as part of the Option Agreement dated May 8, 2025⁴ and Standard will act as operator.

Supplementary geophysical work programs across the Project are also being designed to further refine drill targets for a 2027 drill program. Ongoing geophysical interpretation and modeling is planned throughout the remainder of 2026 to integrate drilling, geophysics, and prospecting datasets, which will further derisk drill targets across the Project prior to follow-up drilling next year.

The Company believes the Project is highly prospective for the discovery of shallow, high-grade^** basement-hosted uranium mineralization akin to the Rabbit Lake deposit and the recently discovered Gemini Mineralized Zone. Located just outside the current margin of the Athabasca Basin, Corvo boasts shallow drill targets with bedrock under minimal cover of glacial till. Several outcrop showings of mineralized veins and fractures are present on the Project, notably the Manhattan Showing that returned modern sample results up to 8.10% U₃O₈ at surface².

Qualified Person Statement

The scientific and technical information contained in this news release has been reviewed and approved by Sean Hillacre, P.Geo., President and VP Exploration of Standard Uranium Ltd. and a “qualified person” as defined in NI 43-101 – Standards of Disclosure for Mineral Projects.

Samples collected for analysis were sent to SRC Geoanalytical Laboratories (“SRC”) in Saskatoon, Saskatchewan for preparation, processing, and ICP-MS multi-element analysis using total and partial digestion and boron by fusion. Basement samples were tested with ICP-MS2 uranium multi-element exploration package plus boron. All sandstone samples, and basement samples marked as radioactive upon arrival to the lab were also analyzed using the U₃O₈ assay (reported in wt.%). Basement rock split interval samples range from 0.1 to 1.0 m. SRC is an ISO/IEC 17025/2005 and Standards Council of Canada certified analytical laboratory. Blanks, standard reference materials, and repeats were inserted into the sample stream at regular intervals in accordance with Standard’s quality assurance/quality control (“QA/QC”) protocols. All samples passed internal QA/QC protocols and the results presented in this release are deemed complete, reliable, and repeatable.

Historical data disclosed in this news release relating to sampling results from previous operators are historical in nature. Neither the Company nor a qualified person has yet verified this data and therefore investors should not place undue reliance on such data. The Company’s future exploration work may include verification of the data. The Company considers historical results to be relevant as an exploration guide and to assess the mineralization as well as economic potential of exploration projects. Any historical grab samples disclosed are selected samples and may not represent true underlying mineralization.

References

¹ News Release: Standard Uranium Confirms Uranium Enrichment in all Winter 2026 Drill Holes at the Corvo Uranium Project, https://www.standarduranium.ca/news-releases/standard-uranium-confirms-uranium-enrichment-in-all-winter-2026-drill-holes-at-the-corvo-uranium-project

² News Release: Standard Uranium Confirms High-Grade Uranium Mineralization up to 8.10% U₃O₈ at Surface on the Corvo Project, https://standarduranium.ca/news-releases/standard-uranium-confirms-high-grade-uranium-mineralization-at-surface-on-the-corvo-project/

³ SMDI# 2052: https://mineraldeposits.saskatchewan.ca/Home/Viewdetails/2052 & Mineral Assessment Report MAW00047: Eagle Plains Resources Inc., 2011-2012

⁴ News Release: Standard Uranium Announces Signing of Definitive Agreement to Option Corvo Project in Eastern Athabasca Basin, https://www.standarduranium.ca/news-releases/standard-uranium-announces-signing-of-definitive-agreement-to-option-corvo-project-in-eastern-athabasca-basin

^*In crystalline basement rocks, the Company considers concentrations of uranium >10 ppm U to be “weakly anomalous”, concentrations >50 ppm U to be “moderately anomalous” and concentrations >100 ppm U to be “highly anomalous”. Intervals represent drilled core lengths; True thicknesses of mineralized zones cannot be determined with certainty at this stage of exploration.

^**The Company considers uranium mineralization with concentrations greater than 1.0 wt.% U₃O₈ to be “high-grade”.

About Aventis Energy Inc. 

Aventis Energy Inc. (CSE: AVE | FRA: C0O0 | OTC: VBAMF) is a mineral exploration company dedicated to the development of strategic projects comprised of battery, base and precious metals in stable jurisdictions. The Company is working to advance its Corvo Uranium & Sting Copper Project.

The Corvo Uranium property has historical drill holes intersected multiple intervals of uranium mineralization, notably along a strike length of 800 metres between historical drill holes TL-79-3 (0.116% U₃O₈ over 1.05 m) and TL-79-5 (0.065% U₃O₈ over 0.15 m)². High-grade* Uranium at Surface with the Manhattan showing (with outcrop samples grab samples returning up to 8.10% U₃O₈) and SMDI showing 2052 (0.137% U₃O₈ and 2,300 ppm Th).

The Sting Copper Project covers approximately 3,700 hectares and recently had results of 54.8m at 0.32% Cu starting at a depth of 27.0m, with higher-grade intervals including six samples (≥0.5m length) ranging from 0.96% to 5.43% Cu. High grade samples of 0.5m at 2.85% Cu and 0.5m at 1.92% Cu with an additional broader interval of 31.1m at 0.27% Cu.

On Behalf of the Board of Directors

Michael Mulberry
Chief Executive Officer, Director
+1 (604) 229-9772
info@vitalbatterymetals.com

Disclaimer for Forward-Looking Information

This news release includes certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” under applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, expect”, “target”, “plan”, “forecast”, “may”, “would”, “could”, “schedule” and similar words or expressions, identify forward-looking statements or information.

Forward-looking statements and forward-looking information relating to any future mineral production, liquidity, enhanced value and capital markets profile of Aventis, future growth potential for Aventis and its business, and future exploration plans are based on management’s reasonable assumptions, estimates, expectations, analyses and opinions, which are based on management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect. Assumptions have been made regarding, among other things, the price of uranium, copper, gold and other metals; costs of exploration and development; the estimated costs of development of exploration projects; Aventis’ ability to operate in a safe and effective manner and its ability to obtain financing on reasonable terms.

This news release contains “forward-looking information” within the meaning of the Canadian securities laws. Statements, other than statements of historical fact, may constitute forward looking information and include, without limitation, statements with respect to the Project and its mineralization potential; the Company’s objectives, goals, or future plans with respect to the Project; further exploration work on the Project in the future; the expected benefits of completing the Program; the commencement of additional drilling program(s) on the Project in the future. With respect to the forward-looking information contained in this news release, the Company has made numerous assumptions regarding, among other things, the geological, metallurgical, engineering, financial and economic advice that the Company has received is reliable and are based upon practices and methodologies which are consistent with industry standards. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: fluctuations in commodity prices and currency exchange rates; uncertainties relating to interpretation of well results and the geology, continuity and grade of uranium, copper, gold and other metal deposits; uncertainty of estimates of capital and operating costs, recovery rates, production estimates and estimated economic return; the need for cooperation of government agencies in the exploration and development of properties and the issuance of required permits; the need to obtain additional financing to develop properties and uncertainty as to the availability and terms of future financing; the possibility of delay in exploration or development programs or in construction projects and uncertainty of meeting anticipated program milestones; uncertainty as to timely availability of permits and other governmental approvals; increased costs and restrictions on operations due to compliance with environmental and other requirements; increased costs affecting the metals industry and increased competition in the metals industry for properties, qualified personnel, and management. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

The Canadian Securities Exchange (CSE) does not accept responsibility for the adequacy or accuracy of this release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/13d8d50a-3944-475c-99f7-a8c5e9da5219

MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE^® (fostamatinib disodium hexahydrate) in Brazil, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.¹

“With today’s launch, TAVALISSE^® is now available to adults in Brazil living with chronic ITP who have not responded adequately to prior therapy. TAVALISSE^® strengthens Knight’s hematology and oncology portfolio in Brazil alongside MINJUVI^® and continues our track record of bringing innovative products to physicians and patients across Latin America,” said Samira Sakhia, President and CEO of Knight Therapeutics.

Knight announced its agreement with Rigel Pharmaceuticals, Inc. in May 2022, securing exclusive rights to commercialize TAVALISSE^® in Latin America. Since entering the agreement, Knight has made significant regulatory progress throughout the region and has submitted TAVALISSE^® for regulatory approval in Brazil, Colombia, Mexico, Argentina and Paraguay and has obtained regulatory approval in Mexico in 2024, Brazil in May 2026, and Colombia in September 2026. The Company launched TAVALISSE^® in Mexico in May 2026.

About TAVALISSE^®

TAVALISSE^® (fostamatinib disodium hexahydrate) is an orally administered spleen tyrosine kinase (SYK) inhibitor. It is currently marketed in the United States under the brand name TAVALISSE (100mg and 150mg tablets) and in Europe under the brand name TAVLESSE for the treatment of adult patients with chronic ITP who have had an insufficient response to a previous treatment.²

TAVALISSE^® is a registered trademark of Rigel Pharmaceuticals, Inc. All other trademarks are the property of their respective owners.

About Chronic Immune Thrombocytopenia (ITP)

In patients with ITP, the immune system attacks and destroys the body’s own blood platelets, which play an active role in blood clotting and healing. Common symptoms of ITP are excessive bruising and bleeding.³ People suffering with chronic ITP may live with an increased risk of severe bleeding events that can result in serious medical complications or even death.⁴

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring, in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.

Forward-Looking Statements for Knight

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2025, as filed on www.sedarplus.ca. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.

References

1. ANVISA, Prescribing Information. Approved on May 7, 2026.
2. Tavalisse. Full Prescribing Information. Rigel Pharmaceuticals, 2018, www.tavalisse.com/downloads/pdf/Tavalisse-Full-Prescribing-Information.pdf.
3. National Heart, Lung, and Blood Institute. Immune Thrombocytopenia. U.S. Department of Health and Human Services, https://www.nhlbi.nih.gov/health/immune-thrombocytopenia. Accessed 24 July 2025.
4. Kos, Marek et al. “The Many Faces of Immune Thrombocytopenia: Mechanisms, Therapies, and Clinical Challenges in Oncological Patients.” Journal of clinical medicine vol. 13,22 6738. 8 Nov. 2024, doi:10.3390/jcm13226738

CONTACT INFORMATION FOR KNIGHT:
Investor Contact:
Knight Therapeutics Inc.
Samira Sakhia	Arvind Utchanah
President & Chief Executive Officer	Chief Financial Officer
T: 514.484.4483	T: 514.484.4483
Email: IR@knighttx.com	Email: IR@knighttx.com
Website: www.knighttx.com	Website: www.knighttx.com

MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE^® (fostamatinib disodium hexahydrate) in Brazil, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.¹

“With today’s launch, TAVALISSE^® is now available to adults in Brazil living with chronic ITP who have not responded adequately to prior therapy. TAVALISSE^® strengthens Knight’s hematology and oncology portfolio in Brazil alongside MINJUVI^® and continues our track record of bringing innovative products to physicians and patients across Latin America,” said Samira Sakhia, President and CEO of Knight Therapeutics.

Knight announced its agreement with Rigel Pharmaceuticals, Inc. in May 2022, securing exclusive rights to commercialize TAVALISSE^® in Latin America. Since entering the agreement, Knight has made significant regulatory progress throughout the region and has submitted TAVALISSE^® for regulatory approval in Brazil, Colombia, Mexico, Argentina and Paraguay and has obtained regulatory approval in Mexico in 2024, Brazil in May 2026, and Colombia in September 2026. The Company launched TAVALISSE^® in Mexico in May 2026.

About TAVALISSE^®

TAVALISSE^® (fostamatinib disodium hexahydrate) is an orally administered spleen tyrosine kinase (SYK) inhibitor. It is currently marketed in the United States under the brand name TAVALISSE (100mg and 150mg tablets) and in Europe under the brand name TAVLESSE for the treatment of adult patients with chronic ITP who have had an insufficient response to a previous treatment.²

TAVALISSE^® is a registered trademark of Rigel Pharmaceuticals, Inc. All other trademarks are the property of their respective owners.

About Chronic Immune Thrombocytopenia (ITP)

In patients with ITP, the immune system attacks and destroys the body’s own blood platelets, which play an active role in blood clotting and healing. Common symptoms of ITP are excessive bruising and bleeding.³ People suffering with chronic ITP may live with an increased risk of severe bleeding events that can result in serious medical complications or even death.⁴

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring, in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.

Forward-Looking Statements for Knight

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2025, as filed on www.sedarplus.ca. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.

References

1. ANVISA, Prescribing Information. Approved on May 7, 2026.
2. Tavalisse. Full Prescribing Information. Rigel Pharmaceuticals, 2018, www.tavalisse.com/downloads/pdf/Tavalisse-Full-Prescribing-Information.pdf.
3. National Heart, Lung, and Blood Institute. Immune Thrombocytopenia. U.S. Department of Health and Human Services, https://www.nhlbi.nih.gov/health/immune-thrombocytopenia. Accessed 24 July 2025.
4. Kos, Marek et al. “The Many Faces of Immune Thrombocytopenia: Mechanisms, Therapies, and Clinical Challenges in Oncological Patients.” Journal of clinical medicine vol. 13,22 6738. 8 Nov. 2024, doi:10.3390/jcm13226738

CONTACT INFORMATION FOR KNIGHT:
Investor Contact:
Knight Therapeutics Inc.
Samira Sakhia	Arvind Utchanah
President & Chief Executive Officer	Chief Financial Officer
T: 514.484.4483	T: 514.484.4483
Email: IR@knighttx.com	Email: IR@knighttx.com
Website: www.knighttx.com	Website: www.knighttx.com

MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE^® (fostamatinib disodium hexahydrate) in Brazil, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.¹

“With today’s launch, TAVALISSE^® is now available to adults in Brazil living with chronic ITP who have not responded adequately to prior therapy. TAVALISSE^® strengthens Knight’s hematology and oncology portfolio in Brazil alongside MINJUVI^® and continues our track record of bringing innovative products to physicians and patients across Latin America,” said Samira Sakhia, President and CEO of Knight Therapeutics.

Knight announced its agreement with Rigel Pharmaceuticals, Inc. in May 2022, securing exclusive rights to commercialize TAVALISSE^® in Latin America. Since entering the agreement, Knight has made significant regulatory progress throughout the region and has submitted TAVALISSE^® for regulatory approval in Brazil, Colombia, Mexico, Argentina and Paraguay and has obtained regulatory approval in Mexico in 2024, Brazil in May 2026, and Colombia in September 2026. The Company launched TAVALISSE^® in Mexico in May 2026.

About TAVALISSE^®

TAVALISSE^® (fostamatinib disodium hexahydrate) is an orally administered spleen tyrosine kinase (SYK) inhibitor. It is currently marketed in the United States under the brand name TAVALISSE (100mg and 150mg tablets) and in Europe under the brand name TAVLESSE for the treatment of adult patients with chronic ITP who have had an insufficient response to a previous treatment.²

TAVALISSE^® is a registered trademark of Rigel Pharmaceuticals, Inc. All other trademarks are the property of their respective owners.

About Chronic Immune Thrombocytopenia (ITP)

In patients with ITP, the immune system attacks and destroys the body’s own blood platelets, which play an active role in blood clotting and healing. Common symptoms of ITP are excessive bruising and bleeding.³ People suffering with chronic ITP may live with an increased risk of severe bleeding events that can result in serious medical complications or even death.⁴

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring, in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.

Forward-Looking Statements for Knight

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2025, as filed on www.sedarplus.ca. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.

References

1. ANVISA, Prescribing Information. Approved on May 7, 2026.
2. Tavalisse. Full Prescribing Information. Rigel Pharmaceuticals, 2018, www.tavalisse.com/downloads/pdf/Tavalisse-Full-Prescribing-Information.pdf.
3. National Heart, Lung, and Blood Institute. Immune Thrombocytopenia. U.S. Department of Health and Human Services, https://www.nhlbi.nih.gov/health/immune-thrombocytopenia. Accessed 24 July 2025.
4. Kos, Marek et al. “The Many Faces of Immune Thrombocytopenia: Mechanisms, Therapies, and Clinical Challenges in Oncological Patients.” Journal of clinical medicine vol. 13,22 6738. 8 Nov. 2024, doi:10.3390/jcm13226738

CONTACT INFORMATION FOR KNIGHT:
Investor Contact:
Knight Therapeutics Inc.
Samira Sakhia	Arvind Utchanah
President & Chief Executive Officer	Chief Financial Officer
T: 514.484.4483	T: 514.484.4483
Email: IR@knighttx.com	Email: IR@knighttx.com
Website: www.knighttx.com	Website: www.knighttx.com

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), today announced that four abstracts featuring preclinical research from their respective immunotherapy programs have been selected for poster presentations at the Society for Immunotherapy of Cancer (SITC) 41^th Anniversary Annual Meeting, taking place November 4-8, 2026, in Phoenix, AZ.

The presentations will feature BriaCell’s personalized off-the-shelf immunotherapy, Bria-OTS+™ and BriaPro’s research on tumor-targeted checkpoint inhibitors, soluble CD80 (BP-80), and engineered CD80 variants.

Presentation details are listed below.

BriaCell

Title: A Multifaceted Genetically Engineered Whole-Cell Vaccine Platform Generates Potent, Broad, Persistent, and Effector-Centric Anti-Tumor Immunity Across Multiple Cancer Indications
Abstract Number: 863
Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6
Date: Friday, Nov. 6, 2026

BriaPro

Title: Development of BP-80, a soluble CD80 dimer (CD80-Fc) for cancer treatment
Abstract Number: 404
Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6
Date: Saturday, Nov. 7, 2026

Title: Tumor-targeted checkpoint inhibitors for reactivation of tumor-infiltrating lymphocytes
Abstract Number: 405
Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6
Date: Friday, Nov. 6, 2026

Title: Molecular design of CD80 variants with increased affinity for PD-L1 and wild-type or lower affinity for CD28
Abstract Number: 406
Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6
Date: Saturday, Nov. 7, 2026

Following the presentation, copies of the posters will be made available at https://briacell.com/scientific-publications/.

About BriaCell Therapeutics Corp.

BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.

About BriaPro Therapeutics Corp.

BriaPro is a pre-clinical stage immunotherapy company developing binding agents and proteins with the intention to boost the ability of the body’s own cancer-fighting cells to destroy cancerous tumors.

Safe Harbor

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about BriaCell and BriaPro presenting posters at the SITC 2026 Annual Meeting, and the contents of such posters, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com

Investor Relations Contact:
investors@briacell.com

New Holiday Program Builds on Three Recent Distribution Center Wins and Expands Edible Garden’s Strategic Presence Across the Midwest, Mid-Atlantic and Northeast

BELVIDERE, NJ, Oct. 06, 2026 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), organic and sustainable produce, and developer of the Zero-Waste Inspired® mission and Farm-to-Formula® platform, today announced that it has been awarded a new fresh herb program with Walmart for the upcoming Thanksgiving through New Year holiday season.

The new holiday program represents incremental business in addition to Edible Garden’s significant existing Walmart distribution and three recently awarded Walmart distribution centers, further expanding the Company’s relationship with one of the world’s largest retailers. Together, these awards strengthen Edible Garden’s position across the Midwest, Mid-Atlantic and Northeast, strategically important markets where the Company believes the combination of Walmart’s substantial retail presence and Edible Garden’s growing fresh herb platform creates a meaningful opportunity to capture additional market share.

The holiday program is designed to meet increased consumer demand during one of the most important selling periods of the year for fresh herbs, as holiday cooking typically drives demand for many of Edible Garden’s core offerings, including rosemary, sage, thyme, parsley, and poultry-blend herbs. Edible Garden is working closely with Walmart on the holiday program across product assortment, production planning, packaging, merchandising, logistics, and replenishment, and preparations for the season are already underway.

To support the new program and the Company’s growing Walmart distribution footprint, Edible Garden plans to leverage its vertically integrated production facilities, strategically located contract grower network, advanced demand-planning capabilities, and proprietary GreenThumb 2.0 technology. Together, these capabilities are designed to provide the flexibility and dependable fulfillment required during periods of elevated demand.

“This award is particularly significant because it represents new business layered onto our already substantial Walmart distribution and follows three recent distribution center wins,” said Jim Kras, Chief Executive Officer of Edible Garden. “Collectively, these programs are strengthening Edible Garden’s position across the Midwest, Mid-Atlantic and Northeast and expanding our participation in some of Walmart’s most important markets. We believe that growing geographic alignment creates an opportunity for both Walmart and Edible Garden to capture additional fresh herb market share while providing consumers with fresher, locally sourced products.

“The Thanksgiving-through-New Year period is one of the most demanding periods of the fresh herb calendar, and our industry-leading fulfillment rate demonstrates our ability to execute at scale. We believe Walmart’s continued expansion of our programs validates the investments we have made in production, distribution, and GreenThumb technology, while deepening our relationship with Walmart and further establishing Edible Garden as a trusted, scalable supply-chain partner to major retailers.”

Edible Garden’s GreenThumb 2.0 platform, together with its network of Company-operated facilities and strategically located contract growers, is designed to more closely align production with anticipated retail demand. This data-driven, localized approach supports the Company’s Zero-Waste Inspired® strategy by helping maintain product freshness and availability while reducing food miles, excess inventory, and shrink throughout the supply chain.

Key Performance Indicator

This press release contains reference to the Company’s fulfillment rate, which is a key performance metric management uses to analyze and measure the Company’s financial performance and results of operation. Management uses fulfillment rate as a measure of current and future business and financial performance, and it may not be comparable with measures provided by other companies. The Company defines fulfillment rate as the percentage of orders filled in full, relative to the total number of orders received during the period.

ABOUT EDIBLE GARDEN^®

Edible Garden AG Incorporated is a leader in controlled environment agriculture (CEA), delivering organic, better-for-you, sustainable produce and products through its Zero-Waste Inspired^® next-generation farming model. Available in over 6,000 retail locations across the United States, Caribbean, and South America, Edible Garden is at the forefront of the CEA and sustainability technology movement, distinguished by its advanced safety-in-farming protocols, sustainable packaging, patented GreenThumb software, and innovative Self-Watering in-store displays. The Company operates state-of-the-art, vertically integrated greenhouses and processing facilities, including Edible Garden Heartland in Grand Rapids, Michigan; Edible Garden Prairie Hills in Webster City, Iowa; and its headquarters at Edible Garden Belvidere in New Jersey. It also partners with a network of contract growers strategically located near major U.S. markets to ensure freshness and reduce environmental impact. The Company is also expanding its Prairie Hills facility in Webster City, Iowa, into a dedicated ready-to-drink (RTD) clean nutrition manufacturing hub, supporting its Farm-to-Formula® strategy and its transformation into higher-margin, shelf-stable nutrition categories.

Edible Garden’s proprietary GreenThumb 2.0 software—protected by U.S. Patents US 11,158,006 B1, US 11,410,249 B2, and US 11,830,088 B2—optimizes vertical and traditional greenhouse growing conditions while aiming to reduce food miles. Its patented Self-Watering display (U.S. Patent No. D1,010,365) is designed to extend plant shelf life and elevate in-store presentation. In addition to its core CEA operations, Edible Garden owns three patents in advanced aquaculture technologies: a closed-loop shrimp farming system (US 6,615,767 B1), a modular recirculating aquaculture setup with automated water treatment and feeding (US 10,163,199 B2), and a sensor-driven ammonia control method utilizing electrolytic chlorine generation (US 11,297,809 B1).

The Company has been recognized as a FoodTech 500 firm by Forward Fooding, is a multi-year participant in Walmart’s Project Gigaton and a Giga Guru designee and has received NRG’s Excellence in Energy Award for its commitment to measurable environmental performance and energy stewardship. Edible Garden also develops and markets a growing line of nutrition and specialty food products, including Vitamin Way^® and Vitamin Whey^®—plant and whey protein powders—and Kick. Sports Nutrition, a premium performance line for health-conscious athletes seeking cleaner, better-for-you options. The Company’s offerings further include fresh, sustainable condiments such as Pulp fermented gourmet and chili-based sauces, as well as Pickle Party, a collection of fermented fresh pickles and krauts.

Learn more at https://ediblegardenag.com.
For Pulp products, visit https://www.pulpflavors.com.
For Vitamin Whey® products, visit https://vitaminwhey.com.
For Kick. Sports Nutrition products, visit https://kicksportsnutrition.net/.
Watch the Company’s latest corporate video here.

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believe,” “expect,” “intend,” “plan,” “expand,” “advance,” “designed to,” “opportunity,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. These statements include, without limitation, statements regarding the Company’s holiday fresh herb program with Walmart, the expected benefits of the Company’s recent Walmart distribution center awards, the Company’s ability to expand its presence and capture additional market share in its key markets, the Company’s available capacity and ability to service additional retail volume, the Company’s ability to deepen its relationship with Walmart and other major retailers, the development of the Company’s ready-to-drink manufacturing facility in Webster City, Iowa, and the Company’s Farm-to-Formula® strategy. There can be no assurance that the holiday program or the Company’s distribution center awards will result in the anticipated volume, revenue or market share gains. Forward-looking statements are based on the Company’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including those described in the “Risk Factors” section and other sections of the Company’s reports filed with the Securities and Exchange Commission. All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:
Crescendo Communications, LLC
212-671-1020
EDBL@crescendo-ir.com

New Holiday Program Builds on Three Recent Distribution Center Wins and Expands Edible Garden’s Strategic Presence Across the Midwest, Mid-Atlantic and Northeast

BELVIDERE, NJ, Oct. 06, 2026 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), organic and sustainable produce, and developer of the Zero-Waste Inspired® mission and Farm-to-Formula® platform, today announced that it has been awarded a new fresh herb program with Walmart for the upcoming Thanksgiving through New Year holiday season.

The new holiday program represents incremental business in addition to Edible Garden’s significant existing Walmart distribution and three recently awarded Walmart distribution centers, further expanding the Company’s relationship with one of the world’s largest retailers. Together, these awards strengthen Edible Garden’s position across the Midwest, Mid-Atlantic and Northeast, strategically important markets where the Company believes the combination of Walmart’s substantial retail presence and Edible Garden’s growing fresh herb platform creates a meaningful opportunity to capture additional market share.

The holiday program is designed to meet increased consumer demand during one of the most important selling periods of the year for fresh herbs, as holiday cooking typically drives demand for many of Edible Garden’s core offerings, including rosemary, sage, thyme, parsley, and poultry-blend herbs. Edible Garden is working closely with Walmart on the holiday program across product assortment, production planning, packaging, merchandising, logistics, and replenishment, and preparations for the season are already underway.

To support the new program and the Company’s growing Walmart distribution footprint, Edible Garden plans to leverage its vertically integrated production facilities, strategically located contract grower network, advanced demand-planning capabilities, and proprietary GreenThumb 2.0 technology. Together, these capabilities are designed to provide the flexibility and dependable fulfillment required during periods of elevated demand.

“This award is particularly significant because it represents new business layered onto our already substantial Walmart distribution and follows three recent distribution center wins,” said Jim Kras, Chief Executive Officer of Edible Garden. “Collectively, these programs are strengthening Edible Garden’s position across the Midwest, Mid-Atlantic and Northeast and expanding our participation in some of Walmart’s most important markets. We believe that growing geographic alignment creates an opportunity for both Walmart and Edible Garden to capture additional fresh herb market share while providing consumers with fresher, locally sourced products.

“The Thanksgiving-through-New Year period is one of the most demanding periods of the fresh herb calendar, and our industry-leading fulfillment rate demonstrates our ability to execute at scale. We believe Walmart’s continued expansion of our programs validates the investments we have made in production, distribution, and GreenThumb technology, while deepening our relationship with Walmart and further establishing Edible Garden as a trusted, scalable supply-chain partner to major retailers.”

Edible Garden’s GreenThumb 2.0 platform, together with its network of Company-operated facilities and strategically located contract growers, is designed to more closely align production with anticipated retail demand. This data-driven, localized approach supports the Company’s Zero-Waste Inspired® strategy by helping maintain product freshness and availability while reducing food miles, excess inventory, and shrink throughout the supply chain.

Key Performance Indicator

This press release contains reference to the Company’s fulfillment rate, which is a key performance metric management uses to analyze and measure the Company’s financial performance and results of operation. Management uses fulfillment rate as a measure of current and future business and financial performance, and it may not be comparable with measures provided by other companies. The Company defines fulfillment rate as the percentage of orders filled in full, relative to the total number of orders received during the period.

ABOUT EDIBLE GARDEN^®

Edible Garden AG Incorporated is a leader in controlled environment agriculture (CEA), delivering organic, better-for-you, sustainable produce and products through its Zero-Waste Inspired^® next-generation farming model. Available in over 6,000 retail locations across the United States, Caribbean, and South America, Edible Garden is at the forefront of the CEA and sustainability technology movement, distinguished by its advanced safety-in-farming protocols, sustainable packaging, patented GreenThumb software, and innovative Self-Watering in-store displays. The Company operates state-of-the-art, vertically integrated greenhouses and processing facilities, including Edible Garden Heartland in Grand Rapids, Michigan; Edible Garden Prairie Hills in Webster City, Iowa; and its headquarters at Edible Garden Belvidere in New Jersey. It also partners with a network of contract growers strategically located near major U.S. markets to ensure freshness and reduce environmental impact. The Company is also expanding its Prairie Hills facility in Webster City, Iowa, into a dedicated ready-to-drink (RTD) clean nutrition manufacturing hub, supporting its Farm-to-Formula® strategy and its transformation into higher-margin, shelf-stable nutrition categories.

Edible Garden’s proprietary GreenThumb 2.0 software—protected by U.S. Patents US 11,158,006 B1, US 11,410,249 B2, and US 11,830,088 B2—optimizes vertical and traditional greenhouse growing conditions while aiming to reduce food miles. Its patented Self-Watering display (U.S. Patent No. D1,010,365) is designed to extend plant shelf life and elevate in-store presentation. In addition to its core CEA operations, Edible Garden owns three patents in advanced aquaculture technologies: a closed-loop shrimp farming system (US 6,615,767 B1), a modular recirculating aquaculture setup with automated water treatment and feeding (US 10,163,199 B2), and a sensor-driven ammonia control method utilizing electrolytic chlorine generation (US 11,297,809 B1).

The Company has been recognized as a FoodTech 500 firm by Forward Fooding, is a multi-year participant in Walmart’s Project Gigaton and a Giga Guru designee and has received NRG’s Excellence in Energy Award for its commitment to measurable environmental performance and energy stewardship. Edible Garden also develops and markets a growing line of nutrition and specialty food products, including Vitamin Way^® and Vitamin Whey^®—plant and whey protein powders—and Kick. Sports Nutrition, a premium performance line for health-conscious athletes seeking cleaner, better-for-you options. The Company’s offerings further include fresh, sustainable condiments such as Pulp fermented gourmet and chili-based sauces, as well as Pickle Party, a collection of fermented fresh pickles and krauts.

Learn more at https://ediblegardenag.com.
For Pulp products, visit https://www.pulpflavors.com.
For Vitamin Whey® products, visit https://vitaminwhey.com.
For Kick. Sports Nutrition products, visit https://kicksportsnutrition.net/.
Watch the Company’s latest corporate video here.

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believe,” “expect,” “intend,” “plan,” “expand,” “advance,” “designed to,” “opportunity,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. These statements include, without limitation, statements regarding the Company’s holiday fresh herb program with Walmart, the expected benefits of the Company’s recent Walmart distribution center awards, the Company’s ability to expand its presence and capture additional market share in its key markets, the Company’s available capacity and ability to service additional retail volume, the Company’s ability to deepen its relationship with Walmart and other major retailers, the development of the Company’s ready-to-drink manufacturing facility in Webster City, Iowa, and the Company’s Farm-to-Formula® strategy. There can be no assurance that the holiday program or the Company’s distribution center awards will result in the anticipated volume, revenue or market share gains. Forward-looking statements are based on the Company’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including those described in the “Risk Factors” section and other sections of the Company’s reports filed with the Securities and Exchange Commission. All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:
Crescendo Communications, LLC
212-671-1020
EDBL@crescendo-ir.com